Search alternatives:
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
821
NIH score.
Published 2025“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
822
List of excluded studies.
Published 2025“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
823
-
824
-
825
Pulsed-pedestal task video demonstrates a trial in the pulsed-pedestal paradigm.
Published 2021Subjects: -
826
-
827
-
828
Steady-pedestal task video demonstrates a trial in the steady-pedestal paradigm.
Published 2021Subjects: -
829
-
830
Averaged contrast sensitivity parameter data (Mean and SD) for the MC and PC pathways by age group.
Published 2021Subjects: -
831
-
832
-
833
-
834
-
835
A Yoga Strengthening Program Designed to Minimize the Knee Adduction Moment for Women with Knee Osteoarthritis: A Proof-Of-Principle Cohort Study
Published 2015“…A secondary objective was to determine whether the program could improve mobility and fitness, and decrease peak KAM during gait. …”
-
836
The effect of the use of a decision aid with individual risk estimation on the mode of delivery after a caesarean section: A prospective cohort study
Published 2019“…</p><p>Methods</p><p>We performed a prospective cohort study. From 2012 to 2014, 483 women in six hospitals, where the DA was used (intervention group), were compared with 441 women in six matched hospitals (control group). …”
-
837
Improved high sensitivity screen for Huntington disease using a one-step triplet-primed PCR and melting curve assay
Published 2017“…The assay was optimized on 30 genotype-known DNAs, and two plasmids p<i>HTT</i>(CAG)<sub>26</sub> and p<i>HTT</i>(CAG)<sub>33</sub> were used to establish the threshold temperatures (TTs) distinguishing normal from expansion-positive samples. …”
-
838
-
839
-
840